These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
780 related articles for article (PubMed ID: 27491654)
1. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654 [TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
3. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373 [TBL] [Abstract][Full Text] [Related]
5. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633 [TBL] [Abstract][Full Text] [Related]
6. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174 [No Abstract] [Full Text] [Related]
7. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma. Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273 [No Abstract] [Full Text] [Related]
11. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients. Ren M; Dai B; Kong YY; Lv JJ; Cai X Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587 [TBL] [Abstract][Full Text] [Related]
12. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704 [TBL] [Abstract][Full Text] [Related]
13. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Okamoto I; Sato H; Tsukahara K Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271 [TBL] [Abstract][Full Text] [Related]
14. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031 [TBL] [Abstract][Full Text] [Related]
16. Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies. Oya K; Nakamura Y; Shen LT; Ishizuki S; Matsusaka S; Fujisawa Y J Dermatol; 2024 Jun; 51(6):807-815. PubMed ID: 38433350 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688 [TBL] [Abstract][Full Text] [Related]
18. The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines. Guan X; Wang H; Ma F; Qian H; Yi Z; Xu B Medicine (Baltimore); 2016 Mar; 95(11):e3134. PubMed ID: 26986169 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma. Kato J; Hida T; Someya M; Sato S; Sawada M; Horimoto K; Fujioka M; Minowa T; Matsui Y; Tsuchiya T; Kitagawa M; Nakata K; Sakata KI; Torigoe T; Uhara H J Dermatol; 2019 Apr; 46(4):328-333. PubMed ID: 30758859 [TBL] [Abstract][Full Text] [Related]
20. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]